## Protocol Section
### Identification Module
**NCT ID:** NCT06424236

**Acronym:** DIAN-TU

**Brief Title:** Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

**Official Title:** A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

#### Organization Study ID Info
**ID:** DIAN-TU-001 (Gant OLE)
#### Organization
**Class:** OTHER
**Full Name:** Washington University School of Medicine
#### Secondary ID Infos
**Domain:** DIAN TTU-12-243040
**ID:** The Alzheimer's Association
**Type:** OTHER_GRANT
**ID:** U01AG042791
**Link:** https://reporter.nih.gov/quickSearch/U01AG042791
**Type:** NIH
**ID:** 2013-000307-17
**Type:** EUDRACT_NUMBER
**ID:** R01AG046179
**Link:** https://reporter.nih.gov/quickSearch/R01AG046179
**Type:** NIH
**Domain:** Spanish Clinical Studies Registry
**ID:** REec-2014-0817
**Type:** REGISTRY
**Domain:** DIAN-TU Tau-15-347219
**ID:** The Alzheimer's Association
**Type:** OTHER_GRANT
**Domain:** File 4401
**ID:** GHR Foundation
**Type:** OTHER_GRANT
**Domain:** HDE 18S84914
**ID:** Alzheimer's Association
**Type:** OTHER
**Domain:** DIAN-TU NG-16-434362
**ID:** The Alzheimer's Association
**Type:** OTHER_GRANT
**ID:** R56AG053267
**Link:** https://reporter.nih.gov/quickSearch/R56AG053267
**Type:** NIH
**ID:** U01AG059798
**Link:** https://reporter.nih.gov/quickSearch/U01AG059798
**Type:** NIH
**ID:** R01AG053267
**Link:** https://reporter.nih.gov/quickSearch/R01AG053267
**Type:** NIH
### Status Module
#### Completion Date
**Date:** 2023-11-13

**Type:** ACTUAL

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-22

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-15

**Overall Status:** TERMINATED

#### Primary Completion Date
**Date:** 2023-08-12

**Type:** ACTUAL

#### Start Date
**Date:** 2020-06-30

**Type:** ACTUAL

**Status Verified Date:** 2024-05

#### Study First Post Date
**Date:** 2024-05-22
**Type:** ACTUAL
**Study First Submit Date:** 2024-04-16
**Study First Submit QC Date:** 2024-05-15
**Why Stopped:** DIAN-TU announced the discontinuation of the DIAN-TU-001 OLE based on findings from an interim efficacy analysis and the status of the drug program.
### Sponsor Collaborators Module

#### Collaborators

**Class:** INDUSTRY

**Name:** Hoffmann-La Roche

**Class:** OTHER

**Name:** Alzheimer's Association

**Class:** NIH

**Name:** National Institute on Aging (NIA)

#### Lead Sponsor

**Class:** OTHER

**Name:** Washington University School of Medicine

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Oversight Has DMC:** True

### Description Module

**Brief Summary:** The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.

**Detailed Description:** Alzheimer's disease (AD) is defined by the presence of abnormal accumulations of amyloid protein (plaques) and tau protein (tangles) in the brain. The double-blind arm of DIAN-TU-001 Master protocol (NCT01760005) tested whether gantenerumab provided a clinical benefit by slowing the onset or the worsening of the disease. A clinical benefit was not observed in the double-blind part of the DIAN-TU-001 study. However, gantenerumab was associated with improvements in measures of amyloid and tau and an improvement in an overall measure of neurodegeneration (when nerve cells in the brain lose function over time). It is not known whether these changes may provide future clinical benefits. Based on this information, an exploratory Open Label Extension (OLE) will further study the effect of gantenerumab on these Alzheimer-related proteins and their relationship to disease progression.

After this final evaluation of study treatment with gantenerumab used in the gantenerumab / solanezumab double-blind arm of the Master protocol (NCT01760005), participants from the double-blind arm known to carry the genetic mutation for AD have been invited to participate in an OLE period to receive active gantenerumab study treatment as part of the DIAN-TU-001 Master protocol. The OLE period of the study planned to provide study treatment with gantenerumab for up to 3 years (36 months).

This study will continue to collect brain scans, blood, and spinal fluid tests (also called biomarkers), as well as cognitive testing. The idea is to determine if gantenerumab has favorable effects on these tests as it may prevent or delay the symptoms of AD.

Update:

Based on the completed studies of gantenerumab in sporadic AD in late 2022, it was decided to determine if dominantly inherited Alzheimer's disease (DIAD) participants in the DIAN-TU-001 OLE study were benefiting from gantenerumab high-dose treatment.

After evaluation, it was decided to discontinue the DIAN-TU-001 gantenerumab OLE.

### Conditions Module

**Conditions:**

- Alzheimers Disease

- Dementia

- Alzheimers Disease, Familial

**Keywords:**

- Alzheimer's

- Alzheimer's Disease

- Dementia

- Mutation

- Genetic Mutation

- Dominantly Inherited Alzheimer's Disease

- Dominantly Inherited Alzheimer Network

- Autosomal Dominant Alzheimer's Disease

- Early Onset Alzheimer's Disease

- DIAN

- DIAN-TU

- DIAN TU

- DIAD

### Design Module

#### Design Info

**Allocation:** NA

**Intervention Model:** SINGLE_GROUP

##### Masking Info

**Masking:** NONE

**Masking Description:** Arm is Open-label as noted in the arm description

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 73

**Type:** ACTUAL

**Phases:**

- PHASE2

- PHASE3

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Gantenerumab: Subcutaneously every 4 weeks, at escalating doses

**Intervention Names:**

- Drug: Gantenerumab

**Label:** Gantenerumab Open Label Extension

**Type:** EXPERIMENTAL

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Gantenerumab Open Label Extension

**Description:** Open-label administered Subcutaneously every 4 weeks at escalating doses

**Name:** Gantenerumab

**Other Names:**

- RO4909832

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** The composite PiB partial volume corrected standardized uptake value ratio is used as the biomarker endpoint for amyloid deposition. Corresponding analyses based on conversion of SUVR to centiloid will be performed by Washington University.

**Measure:** Change in amyloid load as measured by [11C]PiB-PET composite standardized uptake value ration (C-SUVR)

**Time Frame:** Week 0 and Weeks 48, 104, and 156

#### Secondary Outcomes

**Description:** Evaluate the efficacy of gantenerumab in reducing disease progression as assessed in the CDR Sum of Boxes. Minimum score 0; maximum score 18. Higher score indicates worse performance.

**Measure:** Annual Rate of change in Clinical Dementia Rating (CDR) Sum of Boxes

**Time Frame:** Week 0 and Weeks 48, 104, and 156

**Description:** Evaluate the efficacy of gantenerumab in reducing disease progression as assessed in the CDR Global. Minimum score 0; maximum score 3. Higher score indicates worse performance.

**Measure:** Annual Rate of change in Clinical Dementia Rating (CDR) Global

**Time Frame:** Week 0 and Weeks 48, 104, and 156

**Description:** Evaluate the efficacy of gantenerumab in reducing disease progression as assessed in the Functional Assessment Scale (FAS). Higher score indicates worse performance.

**Measure:** Annual Rate of change in Functional Assessment Scale (FAS)

**Time Frame:** Week 0 and Weeks 48, 104, and 156

**Description:** Evaluate the efficacy of gantenerumab in reducing disease progression as assessed in the Mini-Mental State Examination (MMSE). Minimum score 0; maximum score 30. Lower score indicates worse performance.

**Measure:** Annual Rate of change in Mini-Mental State Examination (MMSE)

**Time Frame:** Week 0 and Weeks 48, 104, and 156

**Description:** Evaluate the efficacy of gantenerumab in reducing disease progression as assessed in the Tau PET Binding Partial Volume Corrected Standardized Uptake Value Ratio (Tau PET SUVR)

**Measure:** Annual Rate of change in Tau PET Binding Partial Volume Corrected Standardized Uptake Value Ratio (Tau PET SUVR)

**Time Frame:** Week 0 and Weeks 48, 104, and 156

**Description:** Evaluate the efficacy of gantenerumab in reducing disease progression as assessed in the Cerebrospinal Fluid (CSF) phosphorylated Tau (pTau)-181

**Measure:** Annual Rate of change in Cerebrospinal Fluid (CSF) phosphorylated Tau (pTau)-181

**Time Frame:** Week 0 and Weeks 48, 104, and 156

**Description:** Evaluate the efficacy of gantenerumab in reducing disease progression as assessed in the Neurofilament Light chain (NfL) in CSF (CSF NfL)

**Measure:** Annual Rate of change in Neurofilament Light chain (NfL) in CSF (CSF NfL)

**Time Frame:** Week 0 and Weeks 48, 104, and 156

**Description:** Evaluate the efficacy of gantenerumab in reducing disease progression as assessed in CSF Amyloid Beta1-42/40

**Measure:** Annual Rate of change in Cerebrospinal Fluid (CSF) Amyloid Beta1-42/40

**Time Frame:** Week 0 and Weeks 48, 104, and 156

**Description:** Evaluate the efficacy of gantenerumab in reducing disease progression as assessed in the DIAN-TU OLE Cognitive Composite. The Cognitive Composite is calculated using the WMS-R Digit Span Backward Recall (Minimum score 0; Maximum score 7. Lower indicates worse performance.), the Category Fluency (Animals) value (Minimum score 0; Maximum score Unlimited. Lower score indicates worse performance.), the Wechsler Adult Intelligence Scale Digit Symbol Substitution test (Minimum score 0; Maximum score 93. Lower score indicates worse performance.) , and the Mini Mental State Examination (Minimum score 0; Maximum score 30. Lower score indicates worse performance).

**Measure:** Annual Rate of change in DIAN-TU Open Label Extension Cognitive Composite

**Time Frame:** Week 0 and Weeks 48, 104, and 156

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Between 18-80 years of age
* Individuals who know they have an Alzheimer's disease-causing mutation
* Individuals who have participated in the double-blind period
* In the opinion of the investigator and sponsor, treatment is not contraindicated for safety
* Capable of receiving drug and appropriate clinical safety assessment
* Able to undergo Magnetic Resonance Imaging (MRI), Lumbar Puncture (LP), Positron Emission Tomography (PET), and complete all study related testing and evaluations.
* For women of childbearing potential, if partner is not sterilized, subject must agree to use effective contraceptive measures (hormonal contraception, intra-uterine device, sexual abstinence, barrier method with spermicide).
* Adequate visual and auditory abilities to perform all aspects of the cognitive and functional assessments.
* Has a Study Partner who in the investigator's judgment is able to provide accurate information as to the subject's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion.

Exclusion Criteria:

* History or presence of brain MRI scans indicative of any other significant abnormality
* Alcohol or drug dependence currently or within the past 1 year
* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or foreign metal objects in the eyes, skin or body which would preclude MRI scan.
* History or presence of clinically significant cardiovascular disease, hepatic/renal disorders, infectious disease or immune disorder, or metabolic/endocrine disorders
* Anticoagulants except low dose (≤ 325 mg) aspirin.
* Have been exposed to a monoclonal antibody targeting beta amyloid peptide within the past six months.
* History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years.
* Positive urine or serum pregnancy test or plans or desires to become pregnant during the course of the trial.
* Subjects unable to complete all study related testing, including implanted metal that cannot be removed for MRI scanning, required anticoagulation and pregnancy.

**Healthy Volunteers:** True

**Maximum Age:** 80 Years

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Locations

**Location 1:**

**City:** Birmingham

**Country:** United States

**Facility:** University of Alabama in Birmingham

**State:** Alabama

**Zip:** 35294

**Location 2:**

**City:** La Jolla

**Country:** United States

**Facility:** University of California San Diego Medical Center

**State:** California

**Zip:** 92037

**Location 3:**

**City:** New Haven

**Country:** United States

**Facility:** Yale University School of Medicine

**State:** Connecticut

**Zip:** 06510

**Location 4:**

**City:** Atlanta

**Country:** United States

**Facility:** Emory University

**State:** Georgia

**Zip:** 30329

**Location 5:**

**City:** Indianapolis

**Country:** United States

**Facility:** Indiana University School of Medicine

**State:** Indiana

**Zip:** 46202

**Location 6:**

**City:** Saint Louis

**Country:** United States

**Facility:** Washington University in St. Louis

**State:** Missouri

**Zip:** 63110

**Location 7:**

**City:** Pittsburgh

**Country:** United States

**Facility:** University of Pittsburgh

**State:** Pennsylvania

**Zip:** 15213

**Location 8:**

**City:** Providence

**Country:** United States

**Facility:** Butler Hospital

**State:** Rhode Island

**Zip:** 02096

**Location 9:**

**City:** Seattle

**Country:** United States

**Facility:** University of Washington

**State:** Washington

**Zip:** 98195

**Location 10:**

**City:** Randwick

**Country:** Australia

**Facility:** Neuroscience Research Australia

**State:** New South Wales

**Zip:** 2031

**Location 11:**

**City:** Melbourne

**Country:** Australia

**Facility:** Mental Health Research Institute

**State:** Victoria

**Zip:** 3010

**Location 12:**

**City:** Nedlands

**Country:** Australia

**Facility:** The McCuster Foundation of Alzheimer's Disease Research

**State:** Western Australia

**Zip:** 6009

**Location 13:**

**City:** Vancouver

**Country:** Canada

**Facility:** UBC Hospital

**State:** British Columbia

**Zip:** V6T 2B5

**Location 14:**

**City:** Toulouse

**Country:** France

**Facility:** CHU de Toulouse - Hôpital Purpan

**State:** Haute Garonne

**Zip:** 31059

**Location 15:**

**City:** Lille

**Country:** France

**Facility:** Hopital Roger Salengro - CHU Lille

**State:** Nord

**Zip:** 59037

**Location 16:**

**City:** Paris cedex 13

**Country:** France

**Facility:** Groupe Hospitalier Pitie-Salpetriere

**State:** Paris

**Zip:** 69677

**Location 17:**

**City:** Bron cedex

**Country:** France

**Facility:** Hopital Neurologique Pierre Wertheimer

**State:** Rhone

**Zip:** 69677

**Location 18:**

**City:** Rouen

**Country:** France

**Facility:** CHU de Rouen - Hôpital Charles Nicolle

**State:** Seine Maritime

**Zip:** 76031

**Location 19:**

**City:** Dublin

**Country:** Ireland

**Facility:** St Vincent's University Hospital

**Zip:** DUBLIN 4

**Location 20:**

**City:** San Juan

**Country:** Puerto Rico

**Facility:** University of Puerto Rico, School of Medicine

**Zip:** 00936

**Location 21:**

**City:** Barcelona

**Country:** Spain

**Facility:** Hospital Clínic I Provincial de Barcelona

**Zip:** 8036

**Location 22:**

**City:** London

**Country:** United Kingdom

**Facility:** The National Hospital for Neurology and Neurosurgery

**State:** Greater London

**Zip:** WC1B 3BG

#### Overall Officials

**Official 1:**

**Affiliation:** Washington University School of Medicine

**Name:** Randall J Bateman, MD

**Role:** STUDY_DIRECTOR

### IPD Sharing Statement Module

**Description:** Access to DIAN-TU trial data will follow the DIAN-TU data access policy, which complies with the guidelines established by the Collaboration for Alzheimer's Prevention \[CAP REF\].

**IPD Sharing:** YES

### References Module

#### References

**Citation:** Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11. Erratum In: N Engl J Med. 2012 Aug 23;367(8):780.

**PMID:** 22784036

**Citation:** Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5.

**PMID:** 22672770

**Citation:** Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 2017 Jan;13(1):8-19. doi: 10.1016/j.jalz.2016.07.005. Epub 2016 Aug 29.

**PMID:** 27583651

**Citation:** Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris). 2013 Oct;169(10):737-43. doi: 10.1016/j.neurol.2013.07.017. Epub 2013 Sep 6.

**PMID:** 24016464

**Citation:** Wang G, Berry S, Xiong C, Hassenstab J, Quintana M, McDade EM, Delmar P, Vestrucci M, Sethuraman G, Bateman RJ; Dominantly Inherited Alzheimer Network Trials Unit. A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease. Stat Med. 2018 Sep 20;37(21):3047-3055. doi: 10.1002/sim.7811. Epub 2018 May 14.

**PMID:** 29761523

**Citation:** Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 May;12(5):631-2. doi: 10.1016/j.jalz.2016.04.001. No abstract available.

**PMID:** 27157073

**Citation:** Grill JD, Bateman RJ, Buckles V, Oliver A, Morris JC, Masters CL, Klunk WE, Ringman JM; Dominantly Inherited Alzheimer's Network. A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2015 Jul 22;7(1):50. doi: 10.1186/s13195-015-0135-0. eCollection 2015.

**PMID:** 26203303

**Citation:** McDade E, Bateman RJ. Stop Alzheimer's before it starts. Nature. 2017 Jul 12;547(7662):153-155. doi: 10.1038/547153a. No abstract available.

**PMID:** 28703214

**Citation:** McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ; Dominantly Inherited Alzheimer Network. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018 Oct 2;91(14):e1295-e1306. doi: 10.1212/WNL.0000000000006277. Epub 2018 Sep 14.

**PMID:** 30217935

**Citation:** Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ; Dominantly Inherited Alzheimer Network. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15;83(3):253-60. doi: 10.1212/WNL.0000000000000596. Epub 2014 Jun 13.

**PMID:** 24928124

**Citation:** Weng H, Bateman R, Morris JC, Xiong C. Validity and power of minimization algorithm in longitudinal analysis of clinical trials. Biostat Epidemiol. 2017;1(1):59-77. doi: 10.1080/24709360.2017.1331822. Epub 2017 Jun 13.

**PMID:** 29250611

#### See Also Links

**Label:** Expanded registry

**URL:** http://www.dianexr.org/

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000001927

- Term: Brain Diseases

- ID: D000002493

- Term: Central Nervous System Diseases

- ID: D000009422

- Term: Nervous System Diseases

- ID: D000024801

- Term: Tauopathies

- ID: D000019636

- Term: Neurodegenerative Diseases

- ID: D000019965

- Term: Neurocognitive Disorders

- ID: D000001523

- Term: Mental Disorders

### Condition Browse Module - Browse Branches

- Abbrev: BC10

- Name: Nervous System Diseases

- Abbrev: BXM

- Name: Behaviors and Mental Disorders

- Abbrev: All

- Name: All Conditions

- Abbrev: Rare

- Name: Rare Diseases

### Condition Browse Module - Browse Leaves

- ID: M6904

- Name: Dementia

- Relevance: HIGH

- As Found: Dementia

- ID: M3885

- Name: Alzheimer Disease

- Relevance: HIGH

- As Found: Alzheimer's Disease

- ID: M5204

- Name: Brain Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M5742

- Name: Central Nervous System Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M23002

- Name: Tauopathies

- Relevance: LOW

- As Found: Unknown

- ID: M21558

- Name: Neurodegenerative Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M21836

- Name: Neurocognitive Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M4815

- Name: Mental Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M14473

- Name: Psychotic Disorders

- Relevance: LOW

- As Found: Unknown

- ID: T591

- Name: Autosomal Dominant Multiple Pterygium Syndrome

- Relevance: LOW

- As Found: Unknown

- ID: T2192

- Name: Familial Alzheimer Disease

- Relevance: HIGH

- As Found: Alzheimer's Disease

### Condition Browse Module - Meshes

- ID: D000000544

- Term: Alzheimer Disease

- ID: D000003704

- Term: Dementia

### Misc Info Module

- Version Holder: 2024-05-31
